AG-10 is primarily used in research settings for its potential neuroprotective properties. It has shown promise in studies related to protein misfolding diseases, particularly in models of transthyretin amyloidosis. By stabilizing the tetrameric form of transthyretin, AG-10 helps prevent its dissociation into monomers that can misfold and aggregate into amyloid fibrils, which are associated with cardiac and neurological damage. Due to this mechanism, AG-10 is being investigated as a therapeutic candidate for treating familial amyloid cardiomyopathy (FAC), a condition characterized by the buildup of abnormal amyloid deposits in the heart. Its high selectivity and ability to mimic the protective effects of a natural transthyretin mutation make it a valuable compound in the development of disease-modifying treatments.